Skip to content

Investors & Media


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

lnk Stock Information

Learn More

Creating value by saving sight through transformative science.

Press Releases

15-Nov-21

Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer

11-Nov-21

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and

01-Nov-21

Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the American

lnk News

View All News

Connect with Us
Sign up for ongoing news and events.
Font Resize